Sugi Predict

Sugi Predict / Compounds / SCHEMBL3782020

SCHEMBL3782020

SCHEMBL3782020

CC(C)(C)OC(=O)N1CC(n2nc(I)c3c(N)ncnc32)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 5/20 0.56
▸ JAK2 O60674 2/20 0.56
▸ JAK3 P52333 1/20 0.56
▸ KDR P35968 5/20 0.55
▸ RET P07949 3/20 0.55
▸ SRC P12931 9/20 0.55
▸ CDC7 O00311 1/20 0.55
▸ PLK4 O00444 1/20 0.55
▸ DYRK3 O43781 1/20 0.55
▸ PRKD3 O94806 1/20 0.55
▸ MAP4K4 O95819 1/20 0.55
▸ NTRK1 P04629 1/20 0.55
▸ INSR P06213 1/20 0.55
▸ LCK P06239 1/20 0.55
▸ FYN P06241 1/20 0.55
▸ CDK1 P06493 1/20 0.55
▸ ROS1 P08922 1/20 0.55
▸ FER P16591 1/20 0.55
▸ PRKACA P17612 1/20 0.55
▸ RPS6KB1 P23443 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29588527 1.00 EGFR (0.56) EGFRJAK2JAK3KDRRET
SCHEMBL29588418 0.92 EGFR (0.60) EGFRJAK2JAK3KDRRET
SCHEMBL31574063 0.92 EGFR (0.60) EGFRJAK2JAK3KDRRET
SCHEMBL15345583 0.92 EGFR (0.60) EGFRJAK2JAK3KDRRET
SCHEMBL4824842 0.92 EGFR (0.60) EGFRJAK2JAK3KDRRET
SCHEMBL29799663 0.92 EGFR (0.60) EGFRJAK2JAK3KDRRET
SCHEMBL14706373 0.92 EGFR (0.60) EGFRJAK2JAK3KDRRET
SCHEMBL17073873 0.92 SRC (0.51) EGFRJAK2JAK3KDRRET
SCHEMBL20881689 0.92 SRC (0.51) EGFRJAK2JAK3KDRRET
SCHEMBL24197208 0.91 JAK2 (0.55) EGFRJAK2JAK3KDRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 — — US disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
CN-117597346-A NEK7 inhibitors 哈利亚治疗公司 2024-02-23 — — CN disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 — — EP disclosed
CN-115485281-B FGFR and mutation inhibitor thereof, and preparation method and application thereof 上海和誉生物医药科技有限公司 2023-11-21 — — CN disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 — — US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 — — US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 — — US disclosed
CN-116514806-A Biological inhibitor containing acrylketone, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-08-01 — — CN disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 — — EP disclosed
EP-1385524-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2006-02-01 — — EP disclosed
EP-1379528-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH (DE) 2005-12-07 — — EP disclosed
WO-2005074603-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-08-18 — — WO disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
EP-1379528-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GmbH (DE) 2004-01-14 — — EP disclosed
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2004-01-08 — — US disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed
WO-2002076986-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR3, FGFR1, FGFR4 EGFR 115/4885JAK2 21/4885JAK3 269/4885
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents DPYD, UGT1A1, ABCB1 EGFR 1992/4885JAK2 1515/4885JAK3 1336/4885
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof NR2E1, NR2C2, NR3C1 EGFR 572/4885JAK2 3941/4885JAK3 3636/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 EGFR 4852/4885JAK2 2736/4885JAK3 3396/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 EGFR 2229/4885JAK2 1212/4885JAK3 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.